Spur Therapeutics

Spur Therapeutics was a gene therapy company focused on inherited neurological diseases, with a pipeline of intrathecally delivered AAV gene therapies. Lead candidate SBT101 for adrenomyeloneuropathy (AMN) received FDA Fast Track and Orphan Drug Designation.